| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1009556400 |
| P356 | DOI | 10.1007/S00439-011-0975-Z |
| P8608 | Fatcat ID | release_6ja36i4dtvf7tdxb5uufvtlx6y |
| P932 | PMC publication ID | 3204930 |
| P698 | PubMed publication ID | 21424692 |
| P5875 | ResearchGate publication ID | 50598135 |
| P50 | author | Guy A. Rouleau | Q3121500 |
| Éric Fombonne | Q5386498 | ||
| Laurent Mottron | Q15303095 | ||
| Dan Spiegelman | Q75511254 | ||
| Julie Gauthier | Q75511328 | ||
| Salvatore Carbonetto | Q88062039 | ||
| Ann Marie Craig | Q99353734 | ||
| Jacques L. Michaud | Q102286139 | ||
| Pierre Drapeau | Q113488674 | ||
| Anne Noreau | Q114410040 | ||
| Nathalie Champagne | Q114410149 | ||
| Mathieu Lapointe | Q114410150 | ||
| Ronald G. Lafrenière | Q114410151 | ||
| Ferid Fathalli | Q114410152 | ||
| Marie-Odile Krebs | Q47503005 | ||
| Tabrez J. Siddiqui | Q52280123 | ||
| P2093 | author name string | Fadi F Hamdan | |
| Lynn E DeLisi | |||
| Ridha Joober | |||
| Daisaku Yokomaku | |||
| Peng Huashan | |||
| P2860 | cites work | Neuroligins and neurexins link synaptic function to cognitive disease | Q22251092 |
| Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism | Q24299042 | ||
| A patient with vertebral, cognitive and behavioural abnormalities and a de novo deletion of NRXN1alpha | Q24302161 | ||
| High frequency of neurexin 1beta signal peptide structural variants in patients with autism | Q24306560 | ||
| Reduced social interaction and ultrasonic communication in a mouse model of monogenic heritable autism | Q24307957 | ||
| A neuroligin-4 missense mutation associated with autism impairs neuroligin-4 folding and endoplasmic reticulum export | Q24312193 | ||
| LRRTM1 on chromosome 2p12 is a maternally suppressed gene that is associated paternally with handedness and schizophrenia | Q24324059 | ||
| Mouse neurexin-1alpha deletion causes correlated electrophysiological and behavioral changes consistent with cognitive impairments | Q24328996 | ||
| Neurexins: synaptic cell surface proteins related to the alpha-latrotoxin receptor and laminin | Q24337780 | ||
| X-linked mental retardation and autism are associated with a mutation in the NLGN4 gene, a member of the neuroligin family | Q24534259 | ||
| Functional impact of global rare copy number variation in autism spectrum disorders | Q24596191 | ||
| De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia | Q24621518 | ||
| LRRTMs and neuroligins bind neurexins with a differential code to cooperate in glutamate synapse development | Q24621537 | ||
| Mixed-culture assays for analyzing neuronal synapse formation | Q80093517 | ||
| Recurrent rearrangements in synaptic and neurodevelopmental genes and shared biologic pathways in schizophrenia, autism, and mental retardation | Q24629022 | ||
| Mutations in SYNGAP1 in autosomal nonsyndromic mental retardation | Q24629491 | ||
| Autism genome-wide copy number variation reveals ubiquitin and neuronal genes | Q24629598 | ||
| Disruption of neurexin 1 associated with autism spectrum disorder | Q24643899 | ||
| Disruption of the neurexin 1 gene is associated with schizophrenia | Q24647095 | ||
| Contribution of SHANK3 mutations to autism spectrum disorder | Q24648672 | ||
| Neurexin-neuroligin signaling in synapse development | Q24648824 | ||
| Structural variation of chromosomes in autism spectrum disorder | Q24656970 | ||
| Molecular characterisation of the 22q13 deletion syndrome supports the role of haploinsufficiency of SHANK3/PROSAP2 in the major neurological symptoms | Q24676539 | ||
| LRRTM2 functions as a neurexin ligand in promoting excitatory synapse formation | Q26269925 | ||
| A stoichiometric complex of neurexins and dystroglycan in brain | Q26269938 | ||
| Mapping autism risk loci using genetic linkage and chromosomal rearrangements | Q27315912 | ||
| Comparative genome hybridization suggests a role for NRXN1 and APBA2 in schizophrenia | Q28256580 | ||
| Neurexins: three genes and 1001 products | Q28260363 | ||
| Trans-synaptic interaction of GluRdelta2 and Neurexin through Cbln1 mediates synapse formation in the cerebellum | Q28510819 | ||
| Alpha-neurexins couple Ca2+ channels to synaptic vesicle exocytosis | Q28593220 | ||
| Neuroligin 1: a splice site-specific ligand for beta-neurexins | Q29614429 | ||
| A splice code for trans-synaptic cell adhesion mediated by binding of neuroligin 1 to alpha- and beta-neurexins | Q29620145 | ||
| The neuropathology of schizophrenia. A critical review of the data and their interpretation | Q30573678 | ||
| Induction of GABAergic postsynaptic differentiation by alpha-neurexins | Q33611690 | ||
| Deletions of NRXN1 (neurexin-1) predispose to a wide spectrum of developmental disorders | Q34401694 | ||
| Neurexin 1alpha structural variants associated with autism | Q34779660 | ||
| Autism as a disorder of neural information processing: directions for research and targets for therapy | Q35705869 | ||
| Systematic resequencing of X-chromosome synaptic genes in autism spectrum disorder and schizophrenia. | Q35786397 | ||
| How to build a central synapse: clues from cell culture | Q36336004 | ||
| Sensorimotor gating and schizophrenia. Human and animal model studies | Q38140814 | ||
| LRRTM2 interacts with Neurexin1 and regulates excitatory synapse formation | Q39316804 | ||
| Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients | Q40808959 | ||
| CASK and protein 4.1 support F-actin nucleation on neurexins | Q43768975 | ||
| Deletion of alpha-neurexins does not cause a major impairment of axonal pathfinding or synapse formation | Q48249189 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | autism | Q38404 |
| schizophrenia | Q41112 | ||
| autism spectrum disorder | Q1436063 | ||
| neuroligin family protein binding | Q21102521 | ||
| postsynaptic membrane assembly | Q21109059 | ||
| Neurexin-2 | Q21174835 | ||
| Neurexin-1 | Q21207908 | ||
| Neuroligin 2 | Q21987300 | ||
| Neurexin-1 | Q21990403 | ||
| Neurexin II | Q55186693 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 563-73 | |
| P577 | publication date | 2011-10-01 | |
| P1433 | published in | Human Genetics | Q5937167 |
| P1476 | title | Truncating mutations in NRXN2 and NRXN1 in autism spectrum disorders and schizophrenia | |
| P478 | volume | 130 |
| Q35842364 | A Case of Autism with Ring Chromosome 14. |
| Q37066504 | A Germline Variant in the PANX1 Gene Has Reduced Channel Function and Is Associated with Multisystem Dysfunction |
| Q30366015 | A SLM2 Feedback Pathway Controls Cortical Network Activity and Mouse Behavior. |
| Q28079929 | A Subset of Autism-Associated Genes Regulate the Structural Stability of Neurons. |
| Q38096335 | A matter of balance: role of neurexin and neuroligin at the synapse |
| Q36590631 | A proximity-based method to identify genomic regions correlated with a continuously varying environmental variable |
| Q64896125 | A rare exonic NRXN3 deletion segregating with neurodevelopmental and neuropsychiatric conditions in a three-generation Chinese family. |
| Q47969096 | A targeted sequencing study of glutamatergic candidate genes in suicide attempters with bipolar disorder |
| Q38708466 | Adult Neurogenesis and Psychiatric Disorders |
| Q28069757 | Advancing the understanding of autism disease mechanisms through genetics |
| Q37557787 | An alternative splicing switch shapes neurexin repertoires in principal neurons versus interneurons in the mouse hippocampus |
| Q35286605 | Assessment of 2q23.1 microdeletion syndrome implicates MBD5 as a single causal locus of intellectual disability, epilepsy, and autism spectrum disorder |
| Q92395249 | Assessment of patient clinical descriptions and pathogenic variants from gene panel sequences in the CAGI-5 intellectual disability challenge |
| Q48466433 | Association of neurexin 3 polymorphisms with smoking behavior |
| Q36217805 | Association testing of copy number variants in schizophrenia and autism spectrum disorders |
| Q33619607 | Autism Spectrum Disorders and Schizophrenia Spectrum Disorders: Excitation/Inhibition Imbalance and Developmental Trajectories |
| Q35620380 | Autism beyond diagnostic categories: characterization of autistic phenotypes in schizophrenia |
| Q38981431 | Autism genetics - an overview |
| Q33827328 | Autism spectrum disorder and epileptic encephalopathy: common causes, many questions |
| Q103825975 | Autism-associated miR-873 regulates ARID1B, SHANK3 and NRXN2 involved in neurodevelopment |
| Q33804802 | Autism-like behaviours and enhanced memory formation and synaptic plasticity in Lrfn2/SALM1-deficient mice |
| Q39180685 | Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System |
| Q37605727 | Balance within the Neurexin Trans-Synaptic Connexus Stabilizes Behavioral Control. |
| Q42136181 | CASK stabilizes neurexin and links it to liprin-α in a neuronal activity-dependent manner |
| Q93223361 | Characterization of human mosaic Rett syndrome brain tissue by single-nucleus RNA sequencing |
| Q34069930 | Chronic low-level domoic acid exposure alters gene transcription and impairs mitochondrial function in the CNS. |
| Q28086869 | Common mechanisms of excitatory and inhibitory imbalance in schizophrenia and autism spectrum disorders |
| Q38242378 | Conserved and divergent processing of neuroligin and neurexin genes: from the nematode C. elegans to human |
| Q90866812 | Copy number variant discrepancy resolution using the ClinGen dosage sensitivity map results in updated clinical interpretations in ClinVar |
| Q44672682 | Copy number variant study of bipolar disorder in Canadian and UK populations implicates synaptic genes |
| Q37497448 | CpG sites associated with NRP1, NRXN2 and miR-29b-2 are hypomethylated in monocytes during ageing |
| Q28252135 | Deletion of α-neurexin II results in autism-related behaviors in mice |
| Q27025683 | Developing Medications Targeting Glutamatergic Dysfunction in Autism: Progress to Date |
| Q38223714 | Development of novel therapy of schizophrenia in children and adolescents. |
| Q33581309 | Developmental brain dysfunction: revival and expansion of old concepts based on new genetic evidence |
| Q30432899 | Developmental delays and reduced pup ultrasonic vocalizations but normal sociability in mice lacking the postsynaptic cell adhesion protein neuroligin2. |
| Q35763112 | Dileucine and PDZ-binding motifs mediate synaptic adhesion-like molecule 1 (SALM1) trafficking in hippocampal neurons |
| Q37708396 | Disruption of the ASTN2/TRIM32 locus at 9q33.1 is a risk factor in males for autism spectrum disorders, ADHD and other neurodevelopmental phenotypes |
| Q37496956 | Exome sequencing of extended families with autism reveals genes shared across neurodevelopmental and neuropsychiatric disorders |
| Q39238984 | Exonal elements and factors involved in the depolarization-induced alternative splicing of neurexin 2. |
| Q99563391 | Functional characterization of rare NRXN1 variants identified in autism spectrum disorders and schizophrenia |
| Q36967887 | Genetic circuitry of Survival motor neuron, the gene underlying spinal muscular atrophy |
| Q34539953 | Genetic copy number variation and general cognitive ability |
| Q34349576 | Genetic insights into the functional elements of language |
| Q28649716 | Genetic targeting of NRXN2 in mice unveils role in excitatory cortical synapse function and social behaviors |
| Q84797519 | Genetics of autism spectrum disorders |
| Q40767246 | Genome-wide association study of serum coenzyme Q10 levels identifies susceptibility loci linked to neuronal diseases |
| Q92914432 | Global landscape and genetic regulation of RNA editing in cortical samples from individuals with schizophrenia |
| Q48760685 | Glutamate receptor δ1 induces preferentially inhibitory presynaptic differentiation of cortical neurons by interacting with neurexins through cerebellin precursor protein subtypes |
| Q41543882 | Heterogeneous contribution of microdeletions in the development of common generalised and focal epilepsies |
| Q27334217 | Heterozygous deletion of α-neurexin I or α-neurexin II results in behaviors relevant to autism and schizophrenia |
| Q40637296 | Human Neuropsychiatric Disease Modeling using Conditional Deletion Reveals Synaptic Transmission Defects Caused by Heterozygous Mutations in NRXN1. |
| Q42711564 | Human alpha- and beta-NRXN1 isoforms rescue behavioral impairments of Caenorhabditis elegans neurexin-deficient mutants |
| Q37008928 | Human neurexin-3α antibodies associate with encephalitis and alter synapse development. |
| Q34860194 | Identification of candidate intergenic risk loci in autism spectrum disorder |
| Q30461208 | Identification of rare X-linked neuroligin variants by massively parallel sequencing in males with autism spectrum disorder |
| Q41594457 | IgSF21 promotes differentiation of inhibitory synapses via binding to neurexin2α |
| Q36213513 | Immune system gene dysregulation in autism and schizophrenia. |
| Q37642418 | Impaired hippocampal neuroligin-2 function by chronic stress or synthetic peptide treatment is linked to social deficits and increased aggression. |
| Q28571273 | Interaction between autism-linked MDGAs and neuroligins suppresses inhibitory synapse development |
| Q41460041 | Interplay between maternal Slc6a4 mutation and prenatal stress: a possible mechanism for autistic behavior development |
| Q92237543 | Latrophilins: A Neuro-Centric View of an Evolutionary Conserved Adhesion G Protein-Coupled Receptor Subfamily |
| Q36038760 | Links between genetics and pathophysiology in the autism spectrum disorders |
| Q38239811 | Managing the ethical challenges of next-generation sequencing in genomic medicine |
| Q34764182 | MeCP2 regulates the synaptic expression of a Dysbindin-BLOC-1 network component in mouse brain and human induced pluripotent stem cell-derived neurons. |
| Q38816786 | Modeling the autistic cell: iPSCs recapitulate developmental principles of syndromic and nonsyndromic ASD. |
| Q38093545 | Molecular and clinical characterization of 25 individuals with exonic deletions of NRXN1 and comprehensive review of the literature |
| Q36716971 | Monogenic mouse models of autism spectrum disorders: Common mechanisms and missing links. |
| Q33888417 | Mutation screening of the neurexin 1 gene in thai patients with intellectual disability and autism spectrum disorder |
| Q28259910 | Mutations in NRXN1 in a family multiply affected with brain disorders: NRXN1 mutations and brain disorders |
| Q64237926 | Mutations in and in a patient with early-onset epileptic encephalopathy and respiratory depression |
| Q92027490 | Network-Based Integrative Analysis of Genomics, Epigenomics and Transcriptomics in Autism Spectrum Disorders |
| Q42639812 | Neurexins 1-3 Each Have a Distinct Pattern of Expression in the Early Developing Human Cerebral Cortex. |
| Q102063568 | Neurexins in autism and schizophrenia-a review of patient mutations, mouse models and potential future directions |
| Q83228757 | Neurexophilin4 is a selectively expressed α-neurexin ligand that modulates specific cerebellar synapses and motor functions |
| Q33647511 | Neurodevelopmental disorders: mechanisms and boundary definitions from genomes, interactomes and proteomes |
| Q42320581 | Pan-neurexin perturbation results in compromised synapse stability and a reduction in readily releasable synaptic vesicle pool size |
| Q36589721 | Pathogenetic model for Tourette syndrome delineates overlap with related neurodevelopmental disorders including Autism. |
| Q24610600 | Pathogenic SYNGAP1 mutations impair cognitive development by disrupting maturation of dendritic spine synapses |
| Q36403958 | Phenotypic spectrum and genotype-phenotype correlations of NRXN1 exon deletions. |
| Q36448230 | Physical Interactions and Functional Relationships of Neuroligin 2 and Midbrain Serotonin Transporters |
| Q24300898 | Rare deletions at the neurexin 3 locus in autism spectrum disorder |
| Q45796187 | Rare exonic deletions implicate the synaptic organizer Gephyrin (GPHN) in risk for autism, schizophrenia and seizures |
| Q35844049 | Rare mutations in N-methyl-D-aspartate glutamate receptors in autism spectrum disorders and schizophrenia. |
| Q24632353 | Rate of de novo mutations and the importance of father's age to disease risk |
| Q60112184 | Red fox genome assembly identifies genomic regions associated with tame and aggressive behaviours |
| Q57719675 | Regulation and postsynaptic binding of neurexins — drug targets for neurodevelopmental and neuropsychiatric disorders |
| Q37893976 | Risk factors for autism: translating genomic discoveries into diagnostics |
| Q26766506 | SYNGAP1: Mind the Gap |
| Q37997954 | Schizophrenia genetics: putting all the pieces together |
| Q37350686 | Shank mutant mice as an animal model of autism |
| Q90316321 | Stress-Induced Neuron Remodeling Reveals Differential Interplay Between Neurexin and Environmental Factors in Caenorhabditis elegans |
| Q57267880 | Synaptic Disorders |
| Q47444920 | Synaptic Neurexin Complexes: A Molecular Code for the Logic of Neural Circuits |
| Q35765423 | Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities |
| Q91525839 | Synaptic neurexin-1 assembles into dynamically regulated active zone nanoclusters |
| Q30009298 | Synaptic proteins and receptors defects in autism spectrum disorders |
| Q60938189 | Synaptopathology Involved in Autism Spectrum Disorder |
| Q48513662 | Syndromic autism spectrum disorders: moving from a clinically defined to a molecularly defined approach |
| Q34323019 | Systematic prioritization and integrative analysis of copy number variations in schizophrenia reveal key schizophrenia susceptibility genes |
| Q38837365 | Systemic analysis of osteoblast-specific DNA methylation marks reveals novel epigenetic basis of osteoblast differentiation |
| Q35857541 | Targeted massively parallel sequencing of autism spectrum disorder-associated genes in a case control cohort reveals rare loss-of-function risk variants |
| Q89477367 | The Regulation of Reactive Neuroblastosis, Neuroplasticity, and Nutraceuticals for Effective Management of Autism Spectrum Disorder |
| Q24322902 | The association of GPR85 with PSD-95-neuroligin complex and autism spectrum disorder: a molecular analysis |
| Q34034825 | The genetics of Autism Spectrum Disorders--a guide for clinicians |
| Q37559828 | The role of ionotropic glutamate receptors in childhood neurodevelopmental disorders: autism spectrum disorders and fragile x syndrome. |
| Q28511444 | The specific α-neurexin interactor calsyntenin-3 promotes excitatory and inhibitory synapse development |
| Q64090567 | The within-subject application of diffusion tensor MRI and CLARITY reveals brain structural changes in deletion mice |
| Q62749448 | Transcriptome-wide isoform-level dysregulation in ASD, schizophrenia, and bipolar disorder |
| Q28645671 | Using Gene Ontology to describe the role of the neurexin-neuroligin-SHANK complex in human, mouse and rat and its relevance to autism |
| Q50418437 | Wnt/β-catenin signaling stimulates the expression and synaptic clustering of the autism-associated Neuroligin 3 gene |
| Q38432867 | YY1 Haploinsufficiency Causes an Intellectual Disability Syndrome Featuring Transcriptional and Chromatin Dysfunction |
Search more.